This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Finer, N. Articles by Pagotto, U. Search for Related Content Social Bookmarking                   What's this?

Review: The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management

University of Cambridge, Wellcome Trust Clinical Research Facility, Box 127, Level 5 ACCI, Addenbrooke's Hospital (Box 127), Hills Road, Cambridge, CB2 2QQ, UK, nf237{at}medschl.cam.ac.uk

Uberto Pagotto

Endocrinology Unit and Centro di Ricerca Biomedica Applicata (C.R.B.A), Sant-Orsola-Malpighi Hospital, Via Massarenti 9, 40125, Bologna, Italy

uropean guidelines on cardiovascular disease prevention in clinical practice have identified obesity and smoking as primary risk factors for cardiovascular disease, the increased prevalence of which underlines the need for new therapeutic targets. The endocannabinoid (EC) system is a physiological system, comprising the cannabinoid receptors, cannabinoid type 1 (CB1) and type 2 (CB2), and their natural ligands, such as anandamide and 2-arachidonyl-glycerol (2-AG). The system plays a key role in energy balance regulation, both centrally and peripherally impacting on food intake, lipid and glucose metabolism, and fat accumulation. The EC system is also involved in nicotine dependence. Over activity of the EC system, associated with obesity or chronic tobacco use, leads to increased levels of endogenous ligands (endocannabinoids) and disrupts the feedback mechanism related to steady state homeostasis. Rimonabant, the first selective CB₁ receptor blocker, normalises the EC system, reduces food intake and body weight, improves lipid and glucose metabolism and insulin sensitivity and reduces nicotine self-administration. Clinical trials are ongoing to support the therapeutic potential of rimonabant in reducing these multiple cardiovascular risk factors.

Key Words: obesity • nicotine dependence • metabolic syndrome • cardiovascular risk factors • endocannabinoid system • rimonabant.

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 3, 121-124 (2005)
DOI: 10.1177/14746514050050030201


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?